

Short Report

Open Access

Probing of *Actinobacillus pleuropneumoniae* ApxIIIA toxin-dependent cytotoxicity towards mammalian peripheral blood mononucleated cells

Philippe GAC Vanden Bergh, Laurent LM Zecchinon, Thomas Fett and Daniel Desmecht*

Address: Pathology Department, Faculty of Veterinary Medicine, University of Liege, Colonster Boulevard 20 B43, B-4000 Liege, Belgium

Email: Philippe GAC Vanden Bergh - pvdbergh@student.ulg.ac.be; Laurent LM Zecchinon - lzecchinon@ulg.ac.be;

Thomas Fett - thomas.fett@ulg.ac.be; Daniel Desmecht* - daniel.desmecht@ulg.ac.be

* Corresponding author

Published: 1 December 2008

Received: 6 November 2008

BMC Research Notes 2008, 1:121 doi:10.1186/1756-0500-1-121

Accepted: 1 December 2008

This article is available from: <http://www.biomedcentral.com/1756-0500/1/121>

© 2008 Vanden Bergh et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: *Actinobacillus pleuropneumoniae*, the causative bacterial agent of porcine pleuropneumonia, produces Apx toxins which belong to RTX toxin family and are recognized as the major virulence factors. So far, their target receptor(s) has not been identified and the disease cytopathogenesis remains poorly understood. Production of an active Apx toxin and characterization of its toxic activity constitute the premises necessary to the description of its interaction with a potential receptor. From this point of view, we produced an active recombinant ApxIIIA toxin in order to characterize its toxicity on peripheral blood mononucleated cells (PBMCs) isolated from several species.

Findings: Toxin preparation exercises a strong cytotoxic action on porcine PBMCs which is directly related to recombinant ApxIIIA since preincubation with polymyxin B does not modify the cytotoxicity rate while preincubation with a monospecific polyclonal antiserum directed against ApxIIIA does. The cell death process triggered by ApxIIIA is extremely fast, the maximum rate of toxicity being already reached after 20 minutes of incubation. Moreover, ApxIIIA cytotoxicity is species-specific because llama, human, dog, rat and mouse PBMCs are resistant. Interestingly, bovine and caprine PBMCs are slightly sensitive to ApxIIIA toxin too. Finally, ApxIIIA cytotoxicity is cell type-specific as porcine epithelial cells are resistant.

Conclusion: We have produced an active recombinant ApxIIIA toxin and characterized its specific cytotoxicity on porcine PBMCs which will allow us to get new insights on porcine pleuropneumonia pathogenesis in the future.

Background

Actinobacillus pleuropneumoniae is the bacterial causative agent of porcine pleuropneumonia, a frequent and highly infectious disease generating significant economic losses related to deficits in zootechnical profits and intensive use of antibiotics [1,2]. Bacterium virulence factors include

exotoxins Apx («*A. pleuropneumoniae* RTX») -IA, -IIA, -IIIA and -IVA, lipopolysaccharides, polysaccharidic capsule, fimbriae, iron collecting systems, proteases, superoxide dismutase, etc [3]. Among these weapons, Apx toxins are recognized as major virulence factors. These exotoxins belong to RTX (Repeats in ToXin) proteins family. These latter mol-

ecules share the same structural characteristic which is a series of glycine- and aspartate-rich nonapeptide repeats which constitute the main calcium-binding sites of the protein [4]. If the *apxIVA* gene is not disrupted by an insertion element [5], all serotypes are able to synthesize ApxIVA (only *in vivo*) whose autocatalytic and cross-linking activities [6] make it different from other Apx toxins which are of the pore-forming toxin (PFT) type.

Some of the Apx toxic activities were already detected by precedent studies. It is accepted that: (i) ApxIA exerts a strong hemolytic activity and a strong cytotoxic activity, (ii) ApxIIA possesses a weak hemolytic activity and a moderate cytotoxic activity, and (iii) ApxIIIA does not display a haemolytic activity but a strong cytotoxic activity on porcine neutrophils and pulmonary alveolar macrophages (PAM) [3,7-10]. Contrary to LtxA (*Aggregatibacter actinomycetemcomitans*), LktA (*Mannheimia haemolytica*), HlyA (*Escherichia coli*) and CyaA (*Bordetella pertussis*) RTX toxins for which it was shown that they acted through β_2 -integrin receptors to induce a cytotoxic effect on leukocytes [11-18], the target receptor of PFT Apx toxins has not been identified yet and cytopathogenesis of associated disease remains poorly understood. In this perspective, active Apx toxin production and characterization of its toxic action constitute premises necessary to the description of its interaction with a potential receptor.

Methods

Preparation of rApxIIIA toxin

Plasmid pJFF1003, containing ApxIIIA gene, was kindly provided from P. Kuhnert and J. Frey (Institute of Veterinary Bacteriology, University of Bern, Switzerland). This plasmid contains, inserted in the vector pET14b, the *apxIIICABD* operon controlled by a strong constitutive endogenous promoter [19]. Transformed *E. coli* Rosetta™ (Novagen, Belgium) were seeded on Luria-Bertani (LB) agar plates with ampicillin (50 µg/ml) and incubated overnight at 37°C. Several clones were then cultivated, each one in 200 ml LB broth with ampicillin (50 µg/ml) and the Complete® protease inhibitor cocktail (Roche, Belgium), one tablet for 50 ml culture with shaking (200 rpm) at 37°C until an optic density of 1.2 at 600 nm was reached. Next, the toxin was concentrated following Maier and collaborators protocol [19] and finally dissolved in sterile DPBS (1 ml for 200 ml of starting culture) (Lonza Biowhitaker, Belgium). The ImageJ 1.37c software [20] gave an estimation of ~100 µg/ml (~0.83 µM, ~5.10¹⁴ toxins/ml) ApxIIIA (120 kDa) after electrophoresis on Coomassie blue-stained sodium dodecyl sulfate gels (Invitrogen, Belgium) by using 1 µg of BSA as standard.

PBMCs recovery from several species

Fresh blood rescued from five pigs (*Sus scrofa domesticus*, Piétrain), three wild boars (*Sus scrofa scrofa*), two cows (*Bos Taurus*), two goats (*Capra hircus*), one llama (*Lama*

pacos), a man, two dogs (*Canis familiaris*), ten mice (*Mus musculus*) and two rats (*Rattus norvegicus*) were taken in BD Vacutainer® citrate tube (BD, Belgium). Peripheral blood mononucleated cells (PBMCs) were then extracted by the Accuspin™ System-Histopaque® 1077 (Sigma, Belgium) according to the manufacturer's protocol and resuspended to a density of 2.10⁶ cells/ml in RPMI-1640 with 25 mM Hepes and L-glutamine (Lonza Biowhitaker, Belgium), supplemented with 10% [v/v] heat-inactivated fetal bovine serum (Lonza BioWhittaker, Belgium) along with amphotericin-B 250 µg/ml (Gibco, Belgium) and penicillin-streptomycin 10.000 U/ml (Lonza BioWhittaker, Belgium).

Cell culture

PK15 cell line was purchased from the ATCC collection (CCL-33), maintained in EMEM (Lonza BioWhittaker, Belgium) supplemented with 10% [v/v] heat-inactivated fetal bovine serum (Lonza BioWhittaker, Belgium) along with amphotericin-B 250 µg/ml (Gibco, Belgium) and penicillin-streptomycin 10.000 U/ml (Lonza BioWhittaker, Belgium), at 37°C in a humidified 5% CO₂ incubator and isolated from the flask after treatment with the Cell Dissociation Solution Non Enzymatic (Sigma, Belgium).

Surface labeling of porcine leukocytes and flow cytometry analysis

Localization of the porcine PBMCs on the SSC (Side Scatter)/FSC (Forward Scatter) dot plot was accomplished by a PoLFA-1 cell-surface labeling. First, 10⁵ cells were washed three times with 1 ml DPBS, 1% BSA, by a centrifugation of 5 minutes at 200 g. Next, cellular surface was blocked during 20 minutes on ice with 1 ml DPBS, 1% BSA, and then primary antibody (mouse anti-porcine CD18, MCA1972, Abd Serotec, Belgium) was added at 1/1,000 dilution and incubated for 20 minutes on ice. Cells were washed again three times with DPBS, 1% BSA, and the secondary antibody (AlexaFluor® 488 goat anti-mouse IgG, Molecular Probes, USA) was added at 1/1,000 dilution for 20 minutes on ice. Finally, leukocytes were washed three times with DPBS, resuspended into 500 µl of this buffer and analyzed for AlexaFluor® 488 fluorescence on a BD FACSCanto™ flow cytometry system using BD FACSDiva software (Becton Dickinson, Belgium). Labeling with an isotype-matched non pertinent murine mAb was used as negative control.

Cytotoxicity analysis by flow cytometry

In order to undertake the cytotoxic assays, 5 µg rApxIIIA (50 µl stock solution) were added to 10⁵ PBMCs in 50 µl of RPMI-1640 or 10⁵ PK15 cells in 50 µl of EMEM. The positive and negative controls of cell death were obtained by adding respectively 50 µl paraformaldehyde 10% (Sigma, Belgium) and 50 µl RPMI-1640 or EMEM (mock-exposed) to 10⁵ cells into 50 µl medium. Development of

cell death was stopped by the addition of 1 ml of ice-cold DPBS and pellets were then suspended into 495 μ l DPBS plus 5 μ l propidium iodide (PI) (250 μ g/ml) (Invitrogen, Belgium), after a centrifugation of 5 minutes at 200 g. Finally, the cells susceptibility to rApXIIIa was assayed by measuring PI fluorescence on the BD FACSCanto™ flow cytometry system. Each experiment was made in triplicate.

Findings

Flow cytometric probing of toxin-induced alterations of porcine PBMCs

Flow cytometric analysis of physical characteristics of porcine PBMCs, using SSC/FSC dot plot, revealed a principal cell population (P_1) (Fig. 1A). Anti-porcine (Po) CD18 mAb bound near 100% of P_1 cells (Fig. 1B), confirming that it corresponds to the porcine PBMCs population. P_1 is characterized by FSC and SSC values which presumably correspond to porcine lymphocytes.

After a one hour-incubation with 5 μ g rApXIIIa crude toxin, the SSC/FSC signature of P_1 PBMCs is displaced towards a P_2 population with reduced FSC values (Fig. 1A). Again, surface labeling with the anti-PoCD18 mAb showed that near 100% of P_2 cells correspond to PBMCs (Fig. 1B). Exposition to rApXIIIa thus resulted in a reduction in size with no modification of granularity (SSC). This cellular morphologic change is compatible with the induction of a cell-death process by ApXIIIa [21].

Moreover, in the PI/FSC dot plot (Fig. 1C), it was observed that P_2 is subdivided into a very strongly stained population (P_{2B}) and another showing an intermediate labeling (P_{2A}), presumably corresponding to intermediate stages of cell damage. The cell counts/PI histogram (Fig. 1D) revealed that approximately 70% of porcine PBMCs underwent a cell-death process.

Kinetics of crude toxin preparation cytotoxicity on porcine PBMCs

Kinetics of the cytotoxic action was characterized by incubating 10^5 porcine PBMCs in 50 μ l of RPMI-1640 with 0.3125 μ g rApXIIIa crude toxin and stopping the exposure after 1, 10, 20, 30, 45, 60, 90 and 120 minutes. The results show that cell poisoning is an extremely rapid process. Indeed, one minute incubation is already sufficient to lead to a cytotoxicity rate of approximately ten percents (Fig. 2). Moreover, a plateau of maximal cell death ($\sim 35\%$) is reached after 20 minutes of incubation (Fig. 2). This speed of action was also observed in a precedent study in which marked morphological changes occurred in pulmonary alveolar macrophages within ten minutes of exposure to ApXIIIa [22]. After this period, the toxicity rate seems to increase slightly, following the kinetics of negative controls (Fig. 2).

Dose dependent-cytotoxic activity of crude toxin preparation on porcine PBMCs

As expected, porcine PBMCs were damaged in a concentration-dependent manner when exposed to different dilutions of rApXIIIa crude toxin. Maximum of toxicity rate ($\sim 80\%$) was obtained with the addition of 5 μ g toxin (50 μ l stock solution) to 50 μ l RPMI-1640 with 10^6 porcine PBMCs (Fig. 3). Moreover, the curve of the graph shows that the cytopathogenic rate obtained for this dilution seems to reach a plateau of maximum toxicity (Fig. 3).

Effect of toxin preincubation with polymyxin B on cytotoxicity


In order to examine whether the LPS content possibly present in the crude toxin preparation contributed to the cytotoxicity detected, the toxin preparation was preincubated during one hour at 37°C with polymyxin B (50 and 100 μ g/ml) (Sigma, Belgium) before assaying its cytotoxic activity towards porcine PBMCs. This assay clearly shows that preincubation with polymyxin B does not decrease the cytotoxicity rate and thus, that lipopolysaccharides potentially present in the toxin preparation are not responsible of cell injury induction (Fig. 4A). As negative control, porcine PBMCs were incubated, during the same duration, with the same polymyxin B concentrations without adding the toxin solution.

Cytotoxicity is due to rApXIIIa

Ultimate assignment of the cytotoxic activity to rApXIIIa was made by neutralizing the crude toxin preparation effect via a preincubation of 30 minutes at 4°C with a rabbit monospecific polyclonal antibody directed against ApXIIIa (1/1,000) friendly provided by Professor J. Frey (Institute of Veterinary Bacteriology, University of Bern, Switzerland) [23]. Incubation of the PBMCs during one hour at 37°C with the preincubated mix (crude toxin preparation/antiserum) resulted in a dramatic abatement in the cytopathogenic activity of two different rApXIIIa amounts (0.16 and 0.31 μ g), these latter respectively causing ~ 30 and $\sim 50\%$ of the maximum cell damage recorded (Fig. 3) when the antiserum was omitted (Fig. 4B). Incubating porcine PBMCs in the same conditions with the monospecific polyclonal antiserum directed against ApXIIIa did not alter the baseline cell death rate (Fig. 4B). These results suggest that the cytotoxic activity associated with our crude toxin preparation is due to rApXIIIa.

rApXIIIa-induced cytotoxicity is species-specific

When 10^5 PBMCs purified from pigs, wild boars, cows, goats, llamas, man, dogs, mice and rats were exposed for one hour to 5 μ g rApXIIIa crude toxin, striking differences in susceptibility were enlightened (Fig. 5). Human, llama, dog, mouse and rat PBMCs were totally resistant, whereas

**Figure 1**

A. Spreading of porcine PBMCs elements in SSC/FSC dot plot after rApxIIIa addition. P₁ (red) and P₂ (blue) populations represent mock- (RPMI-1640) and rApxIIIa-exposed porcine PBMCs respectively. X-axis and Y-axis represent FSC and SSC values respectively. **B.** Surface expression of LFA-1 by mock- (P₁, red) and rApxIIIa (P₂, blue) exposed porcine PBMCs. Surface labeling was made with anti-PoCD18 mAb MCA1972. Labeling with an isotype-matched nonpertinent murine mAb was used as negative control (black). X-axis shows fluorescence intensity (Alexa 488) and the Y-axis represents cell count. The percentage of Alexa 488-positive cells is indicated within the panels. **C.** Spreading of porcine PBMCs elements in PI/FSC dot plot after rApxIIIa addition. P₁ (red) and P₂ (blue) populations represent mock- and rApxIIIa-exposed porcine PBMCs respectively. Two subpopulations can be observed for P₂: the first shows an intermediate labeling (P₂A) while the second (P₂B) is very strongly tagged, corresponding to intermediate and final stages of cell death respectively. The bar represents the positivity threshold. X-axis and Y-axis represent FSC and PI-fluorescence values. **D.** Distribution of PI labeling among mock- (red) and rApxIIIa-exposed (blue) porcine PBMCs. The P₂A and P₂B subpopulations are readily detected. X-axis shows fluorescence intensity (PI) and the Y-axis represents cell count. Percentage of PI-positive cells is indicated within the panels.




Figure 2
Kinetics of porcine PBMCs death upon exposition to rApxIIIA crude toxin preparation. Kinetics of the cytotoxic action was characterized by incubating porcine PBMCs with 0.31 μ g rApxIIIA crude toxin preparation and stopping the exposure after 1, 10, 20, 30, 45, 60, 90 and 120 minutes. Horizontal axis, duration of exposition; vertical axis, fraction of PI-positive PBMCs. Basal cell death rate was measured from mock-exposed (RPMI-1640) PBMCs for comparison. Values are means $\pm$ SDs from three representative experiments.

bovine and caprine PBMCs showed slight susceptibility ($\sim 10\%$ PI-positive cells) compared to pig ($\sim 60\%$) and wild boar ($\sim 50\%$) cells.




Figure 3
Dose-dependent cytotoxicity of rApxIIIA on porcine PBMCs. The fraction of PI-positive cells was measured one hour after exposition to serial dilutions of the crude toxin preparation. Values are means $\pm$ SDs from three representative experiments. C-, mock-exposed (RPMI-1640) porcine PBMCs incubated for one hour (negative control); C+, paraformaldehyde-exposed PBMCs (positive control).




Figure 4
A. Effect of polymyxin B incorporation on rApxIIIA-containing crude toxin preparation cytotoxicity towards porcine PBMCs. The fraction of PI-positive cells was measured by flow cytometry after a two-hour exposition (i) to 50 μ l RPMI-1640 (C-), (ii) to 50 μ g/ml or 100 μ g/ml polymyxin B alone (Pol50 and Pol100 respectively), (iii) to 50 μ g/ml or 100 μ g/ml polymyxin B supplemented with 5 μ g rApxIIIA during the second hour (Pol50/Apx and Pol100/Apx), or after a one-hour exposition either (iii) to 5 μ g rApxIIIA alone (Apx) or (iv) to paraformaldehyde 10% (C+). Values are means $\pm$ SDs from three representative experiments. Asterisks (1): PI-positive cell densities significantly higher than that recorded in C-, Pol50 and Pol100 sets of experiments ($P < 0.0001$). PI-positive cell densities retrieved from Pol50/Apx, Pol100/Apx and rApxIIIA groups were not statistically different from each other ($P > 0.5$). **B. Effect of anti-ApxIIIA antibodies incorporation on rApxIIIA-containing crude toxin preparation cytotoxicity towards porcine PBMCs.** The fraction of PI-positive cells was measured by flow cytometry after a one-hour exposition (i) to 50 μ l RPMI-1640 (C-), (ii) to a monospecific anti-ApxIIIA polyclonal antiserum diluted 1/1,000 (Ab-Apx), (iii) to a mix of rApxIIIA (0.31 or 0.16 μ g) and the anti-ApxIIIA polyclonal antiserum diluted 1/1,000 (Ab-Apx + Apx), and (iv) to rApxIIIA alone (Apx) (0.31 or 0.16 μ g). Values are means $\pm$ SDs from three representative experiments. Asterisks (2): positive cell densities significantly higher than that recorded in Ab-Apx + Apx sets of experiments ($P < 0.01$).

rApxIIIA-induced cytotoxicity is leukocytes-specific

Finally, exposing PK15 porcine epithelial cells to 5 μ g rApxIIIA did not result in the induction of cell death, which suggests that cytotoxic activity is restricted to porcine leukocytes (data not shown).

Conclusion

We have produced a recombinant ApxIIIA toxin in order to evaluate its possible cytotoxic activity towards porcine PBMCs. After one-hour duration incubation at 37°C, PBMCs show a reduction in size and accumulate propidium iodide, both characteristics being compatible with




Figure 5
Cytotoxicity of rApxIII A-containing crude toxin preparation towards PBMCs from a set of mammalian species. The fraction of PI-positive cells was measured by flow cytometry after a one-hour exposition to 50 μ l RPMI-1640 (mock), 5 μ g rApxIII A or PAF 10%. Values are means $\pm$ SDs from three representative experiments. Asterisks: species-specific values significantly different from corresponding mock-exposed value ($P < 0.05$). Po, *Sus scrofa domestica* Piétrain; Wb (wild boar), *Sus scrofa scrofa*; Bo, *Bos taurus*; Cap, *Capra hircus*; Llama, *Lama pacos*; Hu, *Homo sapiens*; Dog, *Canis familiaris*; Mu, *Mus musculus*; Rat, *Rattus norvegicus*.

the development of cell death. The cytotoxicity is dose-dependent, develops within minutes, is not susceptible to polymyxin B and is dramatically abated by toxin preincubation with a monospecific polyclonal antiserum directed against ApxIII A, which suggests that the cytopathogenic activity detected is exercised by ApxIII A. The cytotoxicity recorded is specifically directed towards porcine and wild boar PBMCs, even if ruminant leukocytes show slight susceptibility too. Overall, we have shown that ApxIII A shares many functional characteristics with other RTX toxins, i.e. LtxA from *A. actinomycetemcomitans* [24], LktA from *M. haemolytica* [25], HlyA from *E. coli* [26] or CyaA from *B. pertussis* [27], which suggests that it might use the same receptors, the leukocyte β_2 -integrins [11-18]. Recombinant expression of porcine CD11a [28] and CD18 [29] in ApxIII A-resistant cells could answer this question in the future.

Abbreviations

ApX: *Actinobacillus pleuropneumoniae* RTX toxin; Bo: bovine; BSA: bovine serum albumin; DPBS: Dulbecco's phosphate buffer saline; Hu: human; LB: Luria-Bertani; LPS: lipopolysaccharides; Mu: murine; PBMC: peripheral blood mononucleated cells; PI: propidium iodide; PFT: pore-forming toxin; Po: porcine; RPMI-1640: Roswell Park Memorial Institute-1640; RTX: repeats in toxin; Wb: wild boar.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

PVB carried out the design of the study, experiments and the manuscript drafting. TF and LZ participated in the design of the study. DD participated in the design of the study and coordination, and helped to draft the manuscript. All authors read and approved the final manuscript.

Acknowledgements

PVB is the recipient of a studentship from the "Fonds pour la formation à la Recherche dans l'Industrie et l'Agriculture", rue d'Egmont 5, B-1000 Bruxelles. The authors are grateful to Prof. J. Frey and Dr. P. Kuhnert (Institute of Veterinary Bacteriology, University of Bern, Switzerland) for kindly providing the rabbit monospecific polyclonal antibody directed against ApxIII A and plasmid pJFF1003. The authors also thank V. Verleyen (Animal Production Department, University of Liege, Belgium) for giving access to the porcine PBMCs.

References

- Nicolet J: *Actinobacillus pleuropneumoniae*. In *Diseases of swine* 7th edition. Edited by: Leman AD, Straw BE, Mengeling WL, D'Allaire S, Taylor DJ. Ames, IA: Iowa State University Press; 1992:401-408.
- Losinger WC: **Economic impacts of reduced pork production associated with the diagnosis of *Actinobacillus pleuropneumoniae* on grower/finisher swine operations in the United States.** *Prev Vet Med* 2005, **68**:181-193.
- Bosse JT, Janson H, Sheehan BJ, Beddek AJ, Rycroft AN, Kroll JS, Langford PR: ***Actinobacillus pleuropneumoniae*: pathobiology and pathogenesis of infection.** *Microbes Infect* 2002, **4**:225-235.
- Lilie H, Haehnel W, Rudolph R, Baumann U: **Folding of a synthetic parallel beta-roll protein.** *FEBS Lett* 2000, **470**:173-177.
- Tegetmeyer HE, Jones SC, Langford PR, Baltes N: **ISApII, a novel insertion element of *Actinobacillus pleuropneumoniae*, prevents ApXIV-based serological detection of serotype 7 strain AP76.** *Vet Microbiol* 2008, **128**:342-353.
- Osicka R, Prochazkova K, Sulc M, Linhartova I, Havlicek V, Sebo P: **A novel "clip-and-link" activity of repeat in toxin (RTX) proteins from gram-negative pathogens. Covalent protein cross-linking by an Asp-Lys isopeptide bond upon calcium-dependent processing at an Asp-Pro bond.** *J Biol Chem* 2004, **279**:24944-24956.
- Kamp EM, Popma JK, Anakotta J, Smits MA: **Identification of hemolytic and cytotoxic proteins of *Actinobacillus pleuropneumoniae* by use of monoclonal antibodies.** *Infect Immun* 1991, **59**:3079-3085.
- Kamp EM, Stockhofe-Zurwieden N, van Leengoed LA, Smits MA: **Endobronchial inoculation with ApX toxins of *Actinobacillus pleuropneumoniae* leads to pleuropneumonia in pigs.** *Infect Immun* 1997, **65**:4350-4354.
- Cullen JM, Rycroft AN: **Phagocytosis by pig alveolar macrophages of *Actinobacillus pleuropneumoniae* serotype 2 mutant strains defective in haemolysin II (ApXII) and pleurotoxin (ApXIII).** *Microbiology* 1994, **140**(Pt 2):237-244.
- Seah JN, Kwang J: **Localization of linear cytotoxic and proapoptotic epitopes in RTX toxin ApXIII of *Actinobacillus pleuropneumoniae*.** *Vaccine* 2004, **22**:1494-1497.
- Morova J, Osicka R, Masin J, Sebo P: **RTX cytotoxins recognize beta 2 integrin receptors through N-linked oligosaccharides.** *Proc Natl Acad Sci USA* 2008, **105**:5355-5360.
- Kieba IR, Fong KP, Tang HY, Hoffman KE, Speicher DW, Klickstein LB, Lally ET: ***Aggregatibacter actinomycetemcomitans* leukotoxin requires beta-sheets 1 and 2 of the human CD11a beta-propeller for cytotoxicity.** *Cell Microbiol* 2007, **9**:2689-2699.
- Fong KP, Pacheco CM, Otis LL, Baranwal S, Kieba IR, Harrison G, Hersh EV, Boesze-Battaglia K, Lally ET: ***Actinobacillus actinomyce-***

- temcomitans leukotoxin requires lipid microdomains for target cell cytotoxicity.** *Cell Microbiol* 2006, **8**:1753-1767.
14. Li J, Clinkenbeard KD, Ritchey JW: **Bovine CD18 identified as a species specific receptor for *Pasteurella haemolytica* leukotoxin.** *Vet Microbiol* 1999, **67**:91-97.
 15. Jeyaseelan S, Hsuan SL, Kannan MS, Walcheck B, Wang JF, Kehrli ME, Lally ET, Sieck GC, Maheswaran SK: **Lymphocyte function-associated antigen I is a receptor for *Pasteurella haemolytica* leukotoxin in bovine leukocytes.** *Infect Immun* 2000, **68**:72-79.
 16. Lawrence PK, Nelson WVR, Liu W, Knowles DP, Foreyt WJ, Srikumaran S: **beta (2) integrin Mac-1 is a receptor for *Mannheimia haemolytica* leukotoxin on bovine and ovine leukocytes.** *Vet Immunol Immunopathol* 2008, **122**:285-294.
 17. Lally ET, Kieba IR, Sato A, Green CL, Rosenbloom J, Korostoff J, Wang JF, Shenker BJ, Ortlepp S, Robinson MK, Billings PC: **RTX toxins recognize a beta 2 integrin on the surface of human target cells.** *J Biol Chem* 1997, **272**:30463-30469.
 18. Guermontprez P, Khelef N, Blouin E, Rieu P, Ricciardi-Castagnoli P, Guiso N, Ladant D, Leclerc C: **The adenylate cyclase toxin of *Bordetella pertussis* binds to target cells via the alpha(M)beta(2) integrin (CD11b/CD18).** *J Exp Med* 2001, **193**:1035-1044.
 19. Maier E, Reinhard N, Benz R, Frey J: **Channel-forming activity and channel size of the RTX toxins ApxI, ApxII, and ApxIII of *Actinobacillus pleuropneumoniae*.** *Infect Immun* 1996, **64**:4415-4423.
 20. Rasband WS: **ImageJ 1.37c.** 1997 [<http://rsb.info.nih.gov/ij/>]. National Institutes of Health, Bethesda, Maryland, USA
 21. Tarigan S, Slocombe RF, Browning GF, Kimpton W: **Functional and structural changes of porcine alveolar macrophages induced by sublytic doses of a heat-labile, hemolytic, cytotoxic substance produced by *Actinobacillus pleuropneumoniae*.** *Am J Vet Res* 1994, **55**:1548-1557.
 22. Rycroft AN, Williams D, Cullen JM, Macdonald J: **The cytotoxin of *Actinobacillus pleuropneumoniae* (pleurotoxin) is distinct from the haemolysin and is associated with a 120 kDa polypeptide.** *J Gen Microbiol* 1991, **137**(Pt 3):561-568.
 23. Schaller A, Kuhn R, Kuhnert P, Nicolet J, Anderson TJ, MacInnes JL, Segers RP, Frey J: **Characterization of apxIVA, a new RTX determinant of *Actinobacillus pleuropneumoniae*.** *Microbiology* 1999, **145**(Pt 8):2105-2116.
 24. Lally ET, Golub EE, Kieba IR, Taichman NS, Rosenbloom J, Rosenbloom JC, Gibson CV, Demuth DR: **Analysis of the *Actinobacillus actinomycetemcomitans* leukotoxin gene. Delineation of unique features and comparison to homologous toxins.** *J Biol Chem* 1989, **264**:15451-15456.
 25. Lo RY, Strathdee CA, Shewen PE: **Nucleotide sequence of the leukotoxin genes of *Pasteurella haemolytica* A1.** *Infect Immun* 1987, **55**:1987-1996.
 26. Welch RA, Forestier C, Lobo A, Pellett S, Thomas W Jr, Rowe G: **The synthesis and function of the *Escherichia coli* hemolysin and related RTX exotoxins.** *FEMS Microbiol Immunol* 1992, **5**:29-36.
 27. Rose T, Sebo P, Bellalou J, Ladant D: **Interaction of calcium with *Bordetella pertussis* adenylate cyclase toxin. Characterization of multiple calcium-binding sites and calcium-induced conformational changes.** *J Biol Chem* 1995, **270**:26370-26376.
 28. Bergh PG, Vanden, Fett T, Zecchinon LL, Thomas AV, Desmecht DJ: **The CD11a partner in *Sus scrofa* lymphocyte function-associated antigen-I (LFA-I): mRNA cloning, structure analysis and comparison with mammalian homologues.** *BMC Vet Res* 2005, **1**:5.
 29. Lee J-K, Schook LB, Rutherford MS: **Molecular cloning and characterization of the porcine CD18 leukocyte adhesion molecule.** *Xenotransplantation* 1996, **3**:222-230.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

